The Difference Between Relugolix and Degarelix

Relugolix and degarelix are two drugs used to treat prostate cancer. They have some differences in their mechanisms of action and how they are used. Regaglic is an oral hormone therapy drug that is a GnRH receptor antagonist. It reduces the growth of prostate cancer cells by reducing testosterone production in the testicles by inhibiting the release of gonadotropins from the pituitary gland. Repagliflozin is usually taken by mouth once daily and can be used as a single treatment or in combination with other medicines.

Degarelix is used to treat advanced prostate cancer. Degarelix is u200bu200ba synthetic peptide-derived drug that binds to the gonadotropin-releasing hormone (GnRH) receptor in the pituitary gland and blocks the interaction with GnRH. This antagonism reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH), ultimately leading to testosterone suppression. Reducing testosterone is important when treating patients with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids.

The original drug of Regogliflox has not yet been launched in the country, so it is not covered by medical insurance. There are European and Japanese versions of the original drug Rleglik available overseas. The ingredients of the two are basically the same. The price of the European version of 120mg*30 tablets per box may be around RMB 4,000, and the price of the Japanese version of 40mg*100 tablets per box may be around RMB 4,000 (the price may fluctuate due to exchange rates). Currently, there are no generic versions of Repagliflox produced and put on the market.